WuXi Biologics Raises Growth Guidance to 20-23% as "Diamond Funnel" Nears 1,000 Projects and Biosimilars Emerge as New $1 Billion Driver
Interim results call, August 26, 2026: CEO Chris Chen and CFO Ming Tu detail margin expansion, technology moat, and raised full-year guidance
WuXi Biologics delivered a first half that management is calling an inflection point, with revenue growing 18.4% in RMB terms and 23.4% on a constant-currency basis, the fastest pace in four years. The company used the print to raise full-year revenue guidance to 20% to 23% in constant currency, up from a prior range of 16% to 20%, while adjusted gross margin expanded to 48.4%, up 280 basis points year-over-year despite absorbing roughly 300 basis points of FX headwind from RMB appreciation. Strip out currency and the underlying margin expansion was closer to 600 basis points, according to CEO Chris Chen, who told investors the improvement came not from one-off items but from "product mix, utilization and WBS," the company's internal lean-manufacturing system.
Biosimilars emerge as an underappreciated growth lever
The most significant new disclosure on the call was the company's pivot toward biosimilars as a manufacturing growth driver, a segment that has historically been immaterial to WuXi's story. Biosimilars currently represent less than 2% of the 1,064-project portfolio, but management expects this to reach 5% to 7% within a few years, driven by a new cell-line technology that management says can cut a partner's cost of goods by 30% to 50% and shrink the required bioreactor scale from a traditional 12,000-liter steel tank to a 5,000-liter disposable unit. Chen said the company has already signed 20 biosimilar programs for delivery over the next three years, up from under 20 total today, and estimated the segment alone could generate $1 billion in manufacturing revenue within a few years, roughly doubling the company's current manufacturing base. Because biosimilar programs take four to five years from development to commercial launch rather than the eight to ten years typical of novel biologics, management argued this segment will pull forward manufacturing revenue that would otherwise arrive much later in the funnel. On pricing, CFO Ming Tu and Chen clarified that biosimilar contracts are won on technology rather than discount, carrying development pricing 20% to 50% higher than standard programs while manufacturing economics remain comparable to novel drugs.
The funnel economics: from 1,000 projects to a "diamond"
Chen leaned heavily on what he now calls the "diamond funnel," a reference to the portfolio crossing 1,000 total projects (1,064, to be precise) for the first time. He noted it took WuXi 15 years to build its first 1,000 projects but expects the next 1,000 to arrive in just five to six years given the current pace of additions, which grew 43% organically in the first half. Applying rough probability-of-success math across the funnel's roughly 500 preclinical, 300 Phase I, and 130 Phase II programs, Chen estimated the current portfolio could eventually yield 200 to 280 commercial manufacturing programs, versus just 28 today. At an assumed RMB 500 million ($70 million to $80 million) of revenue per commercial program, that translates into a theoretical RMB 100 billion, or roughly $15 billion, of eventual manufacturing revenue embedded in the existing funnel, a figure Chen used to argue that WuXi's growth is structurally underappreciated by the market given biologics manufacturing contracts can run 30 to 40 years once a molecule launches.
Win-the-Molecule strategy accelerates as competitors stumble
WuXi's "Win-the-Molecule" program, in which the company takes over manufacturing for molecules originally developed elsewhere, grew 78% year-over-year, with 16 new wins in the first half including four late-phase programs and one direct commercial win. Chen was candid about why this works: "The reason why we are still able to win the molecule is sometimes our peers actually stumble, and then our clients need to divorce them and remarry, and the new choice they have is WuXi Biologics." The company has now won 128 such programs over eight years with a track record of delivering on every one, a point management uses to argue that WuXi's differentiated cell-line technology, offering up to 10 grams per liter of productivity versus 1 to 3 grams per liter at some competitors, is translating directly into commercial wins by allowing partners to cut cost of goods by 50% or more.
New modality mix continues to shift toward higher-margin, stickier work
Bispecifics and multispecifics now represent 20% of company revenue and are still growing 30%, while ADCs and multispecifics combined account for more than half of the total portfolio and over 70% of new orders signed in the first half. Chen argued this mix shift is structurally beneficial because competitive intensity drops sharply as molecular complexity rises: "For traditional mAbs, maybe there are 10 companies that are as good as us. But once you go to ADCs, maybe only four to five. For multispecifics, only two or three." Three multispecific manufacturing programs are each expected to generate $100 million in annual revenue starting as early as 2027, with the remaining two following in 2028 and 2029.
Royalty economics could be a meaningful profit lever by 2030
Management quantified for the first time the profitability gap between WuXi's royalty-linked CRDMO model and a traditional contract manufacturer. Using a $1 billion-revenue drug as an example with a 5% royalty rate, Chen calculated WuXi's net profit at $53.2 million versus $13.2 million for a traditional CMO providing manufacturing alone, a roughly 4-times differential. The company currently has more than 50 royalty-bearing programs in its portfolio, including CD3 bispecifics partnered with GSK and Merck and a B7-H3 ADC with BioNTech, and management estimates aggregate royalty income could reach $100 million by 2030 and potentially exceed $500 million longer term as programs mature toward commercialization.
Regional mix diversifying, with China reaccelerating from a low base
North America remains the largest market at roughly 60% of revenue, growing 14% off a large base. Europe was flat, largely reflecting the divestiture of the company's Ireland vaccine facility, while China revenue grew 51% as WuXi became more selective, prioritizing higher-margin projects given development teams are already booked at 120% of capacity. Rest of World revenue is approaching 10% of the total. Management flagged that its development organization is essentially at capacity, prompting a 17% year-over-year headcount increase, with manufacturing utilization expected to reach 100% booked next year.
Capacity, quality track record, and capital allocation
IND filing capacity has risen to 300 per year, which management describes as 5 to 10 times peer capacity, while PPQ throughput capacity now supports 40 PPQs, or roughly 20 BLAs, annually. The company reported a 99% success rate across PPQ campaigns over eight years and noted that FDA has waived four pre-license inspections while EMA has waived more than a dozen, a quality record management is positioning as a competitive moat as peers face inspection delays and warning letters. Free cash flow reached RMB 1.5 billion in the first half, a first-half record, supported by RMB 13.7 billion of cash on hand and a low 1.2% gearing ratio. The company plans RMB 7.1 billion of capital expenditure in 2026, rising to approximately RMB 8 billion in 2027 to meet demand, and is actively divesting non-core assets, including its original backup manufacturing business built years ago as a geopolitical hedge, redirecting proceeds toward share buybacks, facility acquisitions in China, and potential M&A. Tu noted the company completed RMB 1.3 billion in share repurchases during the period.
AI-enabled discovery still small but growing fast
In response to an analyst question, Chen disclosed that AI-driven drug discovery services, spanning data generation for third parties, development support once molecules are identified, and WuXi's own AI-discovered assets, are growing 40% annually and now represent roughly 3% of the portfolio. The company said it has discovered six assets using its internal AI models that would not have been feasible through traditional methods and is in licensing discussions for those assets, suggesting a modest but emerging additional revenue stream beyond the core CRDMO business.